Plain-English translation of NCT06479473 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination treatment for advanced small-cell lung cancer that has spread throughout the body. All participants receive chemotherapy drugs (etoposide and cisplatin or carboplatin) combined with an immunotherapy medication called Adebrelimab. Then, some participants will also receive targeted radiation therapy to any remaining tumors, while others will continue with the medication alone.
Extensive-stage small-cell lung cancer is a serious form of cancer that spreads quickly and is difficult to treat. This trial is investigating whether adding radiation therapy to target any leftover tumors after chemotherapy and immunotherapy can help people live longer and prevent their cancer from coming back.
You will receive 4 to 6 cycles of chemotherapy combined with immunotherapy given intravenously every 3 weeks. After this initial treatment, if your cancer has shrunk or stayed stable, you'll be randomly assigned to one of two groups: one that continues with the medication alone for up to 2 years, or one that receives additional radiation therapy to any remaining tumors (completed over 2 weeks) followed by continuing the medication. Throughout the trial, you'll have regular scans and tests to monitor how well the treatment is working.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China